Home / Health / COVID-19 drug candidate priced at $2,340 per patient

COVID-19 drug candidate priced at $2,340 per patient

June 29, 2020 Health Comments Off on COVID-19 drug candidate priced at $2,340 per patient 748 Views

Gilead Sciences has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at $390.

The price for U.S. private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir.

This is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review, last week.

Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS), with the agency and states set to manage allocation to hospitals until the end of September.

HHS has secured more than 500,000 treatment courses of the drug for American hospitals through September, the agency said on Monday.

Remdesivir drug

This represents 100% of Gilead’s projected production for July of 94,200 treatment courses, 90% of production in August and September, in addition to an allocation for clinical trials, HHS said.

After this period, once supplies are less constrained, HHS will stop managing the allocation, Gilead said.

Remdesivir’s price has been a topic of intense debate since the U.S. Food and Drug Administration approved its emergency use in some COVID-19 patients in May. Experts have said that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits.

Wall Street analysts have said the antiviral drug could generate billions of dollars in revenue over the next couple of years if the pandemic continues.

Gilead has tied up with generic drugmakers based in India and Pakistan, including Cipla and Hetero Labs, to make and supply remdesivir in 127 developing countries.

Cipla’s version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab’s version is priced at 5,400 rupees.

Tags

Check Also

QUETTA: Two former chief ministers of Balochistan, Sardar Akhtar Mengal and Dr Abdul Malik Baloch, on Sunday emphasised that the solution to Balochistan’s issues can only be achieved by political means, not through the use of force. They asserted that the country’s future is intricately linked with the supremacy of democracy and the strengthening of political forces. These views were expressed at the 5th Asma Jahangir Conference held in Lahore. Mr Mengal, president of the Balochistan National Party (BNP-Mengal), stated, “If someone wants to resolve the issues of Balochistan, it must be done through political hands, not by guns.” Sardar Mengal stated that there were already rumours before the general election that the BNP would hardly be given a seat. While discussing the matter, he questioned whom to approach for talks. Akhtar Mengal, Malik Baloch urge importance of democracy in shaping the country’s future National Party President Dr Malik Baloch echoed similar thoughts in his speech at the conference. He emphasised that the country’s future hinges on the supremacy of democracy and the strengthening of political parties. He criticised the weakness of political parties, which, he argued, has empowered the establishment to rule the country according to its will. He expressed concerns about the current government and parliament, labelling them as the weakest institutions in history. “At present, the country’s constitution is seeking self-preservation,” he said, adding that elections were rigged across the country, including Balochistan, and the buying and selling of votes was rampant. “Popular public leaders were ousted from parliament, and those brought in were not politically affiliated and had no connection with people,” Dr Malik said, adding that instead of spending heavy sums of money, parliamentary seats were bartered, marking one of the most shameful chapters in political history.

ISLAMABAD: A vaccination campaign to immunise more than 24 million children under the age of …

Managed By: Tech Couplers